Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myeloma
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
April 16th, 2007
Celgene Corporation (NASDAQ:CELG) announced that the Eastern Cooperative Oncology Group (ECOG) has reported that its Data Monitoring Committee's (DMC) review of preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma has found that the use of a low dose of dexamethasone (Decadron) in combination with lenalidomide suggests survival advantage for patients when compared to the higher, standard-dose of dexamethasone that is used in combination with lenalidomide to treat the disease. REVLIMID (lenalidomide) is approved by the U.S. Food and Drug Administration for use as a treatment in combination with standard-dose...
Source: Hematology Week (2007-04-16)
|
